Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Filgotinib (FIL), a Janus kinase-1 preferential inhibitor, has been studied for its efficacy and safety in rheumatoid arthritis. The FINCH3 trial compared FIL monotherapy, FIL plus methotrexate (MTX) combination therapy, and MTX monotherapy in MTX-naïve patients. However, comparisons in patients with an inadequate response to MTX remain unclear. This study aims to evaluate the efficacy and safety of FIL plus MTX versus FIL monotherapy in patients with rheumatoid arthritis who have an inadequate response to MTX.
Methods And Analysis: FAITHFUL (Filgotinib Add-on versus swITcH to Filgotinib in patients with rheUmatoid arthritis who inadequateLy responded to methotrexate) study is a phase IV multicenter, prospective, open-label, randomized controlled trial. Patients with a history of inadequate response to at least 8 weeks of MTX and moderate or high disease activity will be assessed for eligibility at 10 centers in Japan. A history of Janus kinase inhibitor use is an exclusion criterion, but prior use of biologic agents is not considered. Enrolled patients will be randomly assigned in a 1:1 ratio to either the group adding FIL (Add-on group) or the group switching to FIL monotherapy (Switch group). The target sample size is 120 participants. The primary endpoint is the change in DAS28-CRP from baseline to week 24, aiming to assess if the Switch group is non-inferior to the Add-on group. Safety will be evaluated by assessing the incidence of adverse events.
Ethics And Dissemination: The study has received approval from the Certified Review Board of Keio University Hospital (N20230002) and adheres to the principles outlined in the Declaration of Helsinki and good clinical practice standards. Prior to enrollment, all participants provide written informed consent. The findings from this study are intended to be submitted for publication in relevant peer-reviewed journals.
Trial Registration: The trial was registered at Japan Registry of Clinical Trials (jRCTs031230673).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12088685 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0322621 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Natural Products for Regulation of Autoimmune Diseases: Chemical Diversity, Pharmacology, and Therapeutic Applications.
Chem Biodivers
September 2025
Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, Laboratory of Anti-Allergy Functional Compounds, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Autoimmune diseases (AIDs), defined by irregularities in immune system function, pose a substantial health challenge worldwide, impacting millions with persistent and frequently debilitating conditions. Conventional treatments, such as glucocorticoid-based immunosuppressive therapies, are associated with notable drawbacks and limitations. In response to these difficulties, recent scientific efforts have increasingly focused on natural compounds as potential therapeutic agents.
View Article and Find Full Text PDFComment on: Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from FIRST registry.
Rheumatology (Oxford)
September 2025
Department of Rheumatology, Kochi Memorial Hospital, Kochi, Kochi Prefecture, Japan.
Biaryl Phosphate-Based Inhibitors of the Transcription Factor STAT4.
ChemMedChem
September 2025
Institute of Organic Chemistry, Leipzig University, Johannisallee 29, 04103, Leipzig, Germany.
The transcription factor signal transducer and activator of transcription (STAT)4 is a potential target for autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes mellitus. p-Biphenyl phosphate is reported as an inhibitor of the STAT4 Src homology 2 domain, and it is developed to the phosphonate-based inhibitor Stafori-1. Herein, structure-activity relationships of p-biaryl phosphates against STAT4 and their selectivity profiles against other STAT proteins are reported.
View Article and Find Full Text PDFSynovial MS4A4A correlates with inflammation and counteracts response to corticosteroids in arthritis.
Proc Natl Acad Sci U S A
September 2025
Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, United Kingdom.
MS4A4A belongs to the MS4A tetraspan protein superfamily and is selectively expressed by the monocyte-macrophage lineage. In this study, we aimed to evaluate the role of MS4A4A+ macrophages in rheumatoid arthritis (RA) pathogenesis and response to treatment. RNA sequencing and immunohistochemistry of synovial samples from either early treatment-naïve or active chronic RA patients showed that MS4A4A expression positively correlated with synovial inflammation.
View Article and Find Full Text PDFDigital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial.
JAMA Netw Open
September 2025
Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Lübeck, Lübeck, Germany.
Importance: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress; however, access to psychological support remains limited.
Objective: To investigate the effectiveness of a digital psychological intervention for individuals with IRDs.
Design, Setting, And Participants: Participants aged 18 years or older were recruited across Germany between February 22 and June 4, 2024, if they had been diagnosed with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus and reported psychological distress and reduced quality of life.